Clinical Studies of Laser Ablation in Treatment of Primary Liver Carcinoma-Associated Portal Vein Tumor Thrombus

Abstract

Objective: To explore the clinical values of laser ablation as a new treatment for portal vein tumor thrombus (PVTT). Methods: A total of 43 male patients with primary liver carcinoma (PLC)-associated PVTT were randomized into a laser ablation group and a radiotherapy group. The laser ablation group of 21 cases received direct percutaneous laser ablation under ultrasonographic guide, followed by direct injection into the portal vein with chemotherapy drugs including mitomycin C (MMC) and fluorouracil (5-Fu). The radiotherapy group of 22 cases was treated with X-ray in three-dimensional conformal radiotherapy (3D CRT) once a day for a total of 10 days course. After the treatment, all patients were followed for postoperative adverse reactions, changes of tumor thrombus, and survival time. Results: In comparison with the radiotherapy, laser ablation resulted in decreased postoperative complications such as limb fatigue, ascites, upper gastrointestinal ulcer, and bleeding. The overall remission rates (complete remission [CR] + partial remission [PR]) were 61.9% (13/21) and 31.8% (7/22) in the laser ablation and radiotherapy group, respectively, with a significant difference (P < .05). All cases in the laser group showed clinical improvement and the average survival time prolonged to greater than 19.5 months (P < .002). Conclusion: Percutaneous laser ablation to PVTT is an effective, safe, and simply procedure and has proven to offer significant clinical outcomes in the treatment of PLC-associated PVTT.

Keywords

laser ablation portal vein tumor thrombus X-ray in three-dimensional conformal radiotherapy

References

Stuart KE , Anand AJ , Jenkins RL Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217-2222.

Ikai I. , Arii S. , Kojiro M. , et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101: 796-802.

Fuster J. , Garcia-Valdecasas JC , Grande L. , et al. Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg. 1996;223:297-302.

Calvet X. , Bruix J. , Gines P. , et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990;12:753-760.

Portolani N. , Coniglio A. , Ghidoni S. , et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg . 2006;243: 229-235.

Llovet JM , Bustamante J. , Castells A. , et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29: 62-67.

Villa E. , Moles A. , Ferretti I. , et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32:233-238.

Lu ZH , Shen F. , Yuan GX , et al. Percutaneous laser ablation in the treatment of portal vein tumor thrombus in 93 hepatocellular carcinoma patients [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2007; 29(6):449-452.